6533b821fe1ef96bd127c4ee
RESEARCH PRODUCT
Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.
Ruzena TkacovaKirill ZykovNeven TudorićAlvils KramsMarc MiravitllesAdam BarczykKosta KostovArschang ValipourAttila SomfayJan ŠVancaraZuzana ZbozinkovaVladimir KoblizekJurij SorliBranislava Milenkovicsubject
Pulmonary and Respiratory MedicineMalePediatricsmedicine.medical_specialtyChronic bronchitisCross-sectional studyInternational CooperationPopulationVital CapacityComorbidity03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumemedicinePrevalenceHumans030212 general & internal medicineeducationBronchitisAgededucation.field_of_studyCOPDbusiness.industryData CollectionSmokingTobacco Use DisorderMiddle Agedmedicine.diseaseComorbidityrespiratory tract diseases3. Good healthEastern europeanBronchitis ChronicEuropeCross-Sectional StudiesPhenotypeTreatment Outcome030228 respiratory systemCohortBronchitisFemalebusinessdescription
Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region.Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment.3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequent exacerbators with chronic bronchitis, 9.5% frequent exacerbators without chronic bronchitis and 6.9% were classified as asthma–COPD overlap. Differences in the distribution of phenotypes between countries were observed, with the highest heterogeneity observed in the nonexacerbator cohort and the lowest heterogeneity observed in the asthma–COPD cohort. There were statistically significant differences in symptom load, lung function, comorbidities and treatment between these phenotypes.The majority of patients with stable COPD in CEE are nonexacerbators; however, there are distinct differences in surrogates of disease severity and therapy between predefined COPD phenotypes.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-05-01 | The European respiratory journal |